



BMT CTN PROTOCOL #0401

A Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Deletions are noted in strike-out text and additions are noted in italicized text.

Significant Changes to Version 5.0 of the Protocol:

- §2.2.1 Patient Inclusion Criteria #5:
 - Revised text to read: “~~Disease status of primary induction failure, first relapse or second complete remission.~~ All patients must have chemosensitive disease as demonstrated by at least a partial response (as defined by the criteria in Chapter 3) to induction or salvage therapy.”